# Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

> **NCT06420440** · PHASE2 · RECRUITING · sponsor: **Chen Xiaoping** · enrollment: 160 (estimated)

## Conditions studied

- HCC

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Lenvatinib
- **DRUG:** Tislelizumab
- **PROCEDURE:** Liver resection
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06420440
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06420440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06420440, "Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06420440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*